C3-Symmetric Ligands in Drug Design: When the Target Controls the Aesthetics of the Drug

Molecules. 2023 Jan 10;28(2):679. doi: 10.3390/molecules28020679.

Abstract

A number of proteins are able to adopt a homotrimeric spatial conformation. Among these structures, this feature appears as crucial for biologic targets, since it facilitates the design of C3-symmetric ligands that are especially suitable for displaying optimized ligand-target interactions and therapeutic benefits. Additionally, DNA as a therapeutic target, even if its conformation into a superhelix does not correspond to a C3-symmetry, can also take advantage of these C3-symmetric ligands for better interactions and therapeutic effects. For the moment, this opportunity appears to be under-exploited, but should become more frequent with the discovery of new homotrimeric targets such as the SARS-CoV2 spike protein. Besides their potential therapeutic interest, the synthetic access to these C3-symmetric ligands often leads to chemical challenges, although drug candidates with an aesthetic structure are generally obtained.

Keywords: C3; drug design; homo-trimeric; symmetry.

Publication types

  • Review

MeSH terms

  • COVID-19*
  • Drug Design
  • Humans
  • Ligands
  • RNA, Viral*
  • SARS-CoV-2

Substances

  • Ligands
  • RNA, Viral

Grants and funding

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 765704.